Roche Holdings AG Basel (RHHBY) Research Coverage Started at Wolfe Research

Wolfe Research initiated coverage on shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) in a report issued on Tuesday morning, The Fly reports. The brokerage issued a market perform rating on the stock.

A number of other brokerages have also issued reports on RHHBY. ValuEngine lowered Roche Holdings AG Basel from a hold rating to a sell rating in a research report on Tuesday, August 7th. Cowen reissued a buy rating and issued a $34.00 target price on shares of Roche Holdings AG Basel in a research report on Thursday, July 26th. Zacks Investment Research raised Roche Holdings AG Basel from a hold rating to a strong-buy rating and set a $35.00 target price on the stock in a research report on Wednesday, September 12th. Finally, Bank of America lowered Roche Holdings AG Basel from a buy rating to a neutral rating in a research report on Monday, September 10th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $34.50.

RHHBY stock opened at $29.32 on Tuesday. The company has a market cap of $209.30 billion, a PE ratio of 15.04, a PEG ratio of 1.94 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.97 and a current ratio of 1.28. Roche Holdings AG Basel has a one year low of $26.30 and a one year high of $32.42.



Hedge funds and other institutional investors have recently made changes to their positions in the business. Mechanics Bank Trust Department purchased a new stake in Roche Holdings AG Basel in the third quarter valued at approximately $207,000. Cornerstone Investment Partners LLC purchased a new stake in Roche Holdings AG Basel in the third quarter valued at approximately $206,000. Dearborn Partners LLC purchased a new stake in Roche Holdings AG Basel in the third quarter valued at approximately $232,000. Gardiner Nancy B purchased a new stake in Roche Holdings AG Basel in the third quarter valued at approximately $454,000. Finally, Chartwell Investment Partners LLC purchased a new stake in Roche Holdings AG Basel in the second quarter valued at approximately $743,000. 0.56% of the stock is currently owned by institutional investors.

About Roche Holdings AG Basel

Roche Holding AG engages in the diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Read More: How Do You Make Money With Penny Stocks?

The Fly

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply